← All trials
NCT03583125
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 29, 2018
- Primary completion
- May 29, 2019
- Completion date
- Nov 29, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 140
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- EddingPharm Oncology Co., LTD.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.